Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer ...Middle East

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up...

Hence then, the article about oncoinvent reports positive final data from phase 1 trial of radspherin to treat ovarian cancer was published today ( Wednesday 08/10/2025 - 08:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer )

Also on site :

• UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
• Scott Ritter say he was ‘de-banked’
• AI boom fuels fears of an industry bubble (VIDEO)